Alere Inc: (NYSE: ALR)
$26.53
0.07 (0.27%)
Volume 1,282,796
May 21 04:02 PM ET
Zacks Rank: 4-Sell 
| #4 |
Overview Quote
Stock Activity
| Day Low - High | 26.00 - 27.27 |
| 52wk Low - High | 17.13 - 29.57 |
| Previous Close | 26.46 |
| Avg. Volume | 731,355 |
| Industry | MED PRODUCTS |
| Market Cap | 2.15 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.50 |
| PE (Forward) | 12.88 |
| Current Year Est. | 2.06 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 4 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
179 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 12.88 |
| PEG Ratio | 1.03 |
| Current Year Est. | 2.06 |
| Current Quarter Estimate | 0.39 |
| Most Accurate Estimate | 0.39 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | 1.93 |
| Expected Earnings Growth | 12.50% |
Company Description
Alere Inc., formerly known as Inverness Medical Innovations, Inc., provides products and services, which focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.39 | 0.36 | 2.06 | 2.56 |
| Number of Estimates | 1 | 1 | 2 | 2 |
| Low Estimate | 0.39 | 0.36 | 1.88 | 2.40 |
| High Estimate | 0.39 | 0.36 | 2.23 | NA |
| Year Ago EPS | 0.43 | 0.48 | 2.15 | 2.06 |
| EPS Growth | -9.30% | -25.00% | -4.42% | 24.57% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ALERE INC | ALR | 26.46 | |
|
| CONCEPTUS INC | CPTS | 30.92 | |
|
| ATRICURE INC | ATRC | 9.05 | |
|
| INVIVO THERAPT | NVIV | 2.89 | |
|
| TRANS1 INC | TSON | 1.69 | |
|
| ABAXIS INC | ABAX | 44.67 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| BAXTER INTL | BAX | 72.94 | |
|
| BIO-RAD LABS -A | BIO | 116.41 | |
|
| BIOLIFE SOL INC | BLFS | 0.41 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Alere Beats Earnings Est, Turns to Profit
May 10, 2013
Zacks Rank #5 Additions for Thursday
Apr 18, 2013
Alere Launches AMR Campaign
Mar 18, 2013
Alere Extends Deal with Virtua
Mar 08, 2013
Alere Beats in 4Q, Reduces Loss
Feb 19, 2013
Epocal Acquired by Alere
Feb 12, 2013
Alere Closes Debt Offering
Dec 13, 2012
Alere Plans to Sell Notes
Nov 28, 2012
Financials
| EPS TTM | 1.93 |
| Sales | 2,819 |
| Net Income | -72 |
| Price/Earnings | 13.71 |
| Price/Book | 1.41 |
| Price/Cash Flow | 3.40 |
| Price/Sales | 0.74 |
News
1 Reason Alere May Be Headed for a Slowdown - TheMotleyFool
May 21, 2013
Alere (ALR) Showing Bullish Technicals With Resistance At $26.77 - Freshbrewedmedia
May 21, 2013
Alere is Among the Companies in the Health Care Supplies Industry With the Highest Forward Earnings Yield (ALR, XRAY, UTMD) - Financial News Network Online - News Corner
May 21, 2013
Craig-Hallum Made the Right Call, Alere 1.3% Lower (ALR) - Financial News Network Online - News Corner
May 21, 2013
Volume Spike Detected in Shares of Alere as They Move Higher on 1.4x Above-Average Volume (ALR) - Financial News Network Online - Unusual Volume
May 21, 2013
Alere Earnings Review: 9 Days after Announcement Shares Down 2.2% (ALR) - Financial News Network Online - Earnings Lookback
May 18, 2013
Is Alere`s Cash Flow Just For Show? - TheMotleyFool
May 17, 2013
Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock - Pr Newswire
May 16, 2013
Broker Recommendations
| Current ABR | 2.11 |
| ABR (Last Week) | 2.11 |
| # of recs in ABR | 9 |
| Average Target Price | 29.50 |
| Industry Rank by ABR | 179 out of 265 |
| Rank in Industry | 62 out of 72 |
